Prime Medicine (NASDAQ:PRME) Shares Gap Up - Time to Buy?

Key Points

• Prime Medicine's stock gapped up from a previous close of $4.67 to open at $4.87, ultimately trading at $4.81 with a volume of over 1 million shares.
• Wall Street Zen has downgraded Prime Medicine from a "hold" rating to a "sell" rating as of September 2nd.
• The company has a market capitalization of $647.28 million, a price-to-earnings ratio of -3.08, and a beta of 2.38, indicating potential volatility.

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $4.67, but opened at $4.87. Prime Medicine shares last traded at $4.81, with a volume of 1,046,806 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded Prime Medicine from a "hold" rating to a "sell" rating in a research note on Tuesday, September 2nd.

Prime Medicine Stock Down 4.5%

The firm has a market capitalization of $658.07 million, a PE ratio of -3.13 and a beta of 2.38.

Prime Medicine Company Profile

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.